Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

What is it about?

- People with prediabetes or type 2 diabetes, in particular when associated with obesity, are at a high risk of developing NAFLD, therefore risk stratified for their risk of developing cirrhosis. - Management is best within a multidisciplinary team and should include lifestyle changes that reverse excess body weight (including structured weight loss programs, bariatric surgery and/or pharmacotherapy as needed, especially glucagon-like peptide-1 receptor agonists) and cardiometabolic risk reduction. - Some pharmacological treatments for type 2 diabetes, such as pioglitazone and glucagon-like peptide-1 receptor agonists, can reverse steatohepatitis and slow fibrosis progression.

Featured Image